

VARDHAMAN

Vardhaman Laboratories Limited

REGD. OFFICE : 1393, Peth Bhag, High School Road, P.O.Box 184, SANGLI 416 416.

Tel: (0233) 2623886, 2623310 Fax: (0233) 2620467 E-mail: vll@vsnl.com

FACTORY : J-5, MIDC, Kupwad, SANGLI 416 436.

L85195PN1985PLC036017

26th July, 2017

To,

The Secretary
Bombay Stock Exchange Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001

Dear Sirs,

Ref.:- Scrip Code 524796

Sub.:- Submission of Revised Audited Financial Results for the quarter and year ended 31st March, 2017.

With reference to the email received for BSE on 10th July, 2017 regarding Discrepancies in Financial Result of the Company for the Quarter \ Year ended March 2017 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith

1. Revised Audited Financial Results of our Company for the quarter and year ended 31st March, 2017 along with Auditors Report thereon dated 30th May, 2017 issued by M/s. Agrawal Naredi & Co, Statutory Auditors of the Company.
2. Disclosure of the impact of Audit Qualification under Regulation 33/52 of SEBI (LODR), (Amendment) Regulations, 2016.
3. Statement of Assets & Liabilities for quarter and year ended 31st March, 2017.

The above statement is taken on record by the Board of Directors at its meeting held on 30th May, 2017.

You are requested to take the same on your records.

Very truly yours,

For Vardhaman Laboratories Limited



SUNIL SHAH
Managing Director
(DIN:00321471)

Encl.:- As above.

AGRAWAL NAREDI & CO.**CHARTERED ACCOUNTANTS**

391, NARAYAN PETH, PUNE- 411 030

DATE -30/05/2017

**AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF
THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS
AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

To
Board of Directors of
M/s. Vardhaman Laboratories Limited.

We have audited the quarterly financial results of M/s. Vardhaman Laboratories Limited for the quarter ended 31st March, 2017 and the year to date results for the period 01st April, 2016 to 31st March, 2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and

- (ii) give a true and fair view of the net profit/ loss and other financial information for the quarter ended 31st March, 2017 as well as the year to date results for the period from 01st April, 2016 to 31st March, 2017.

**For Agrawal Naredi & Co.,
Chartered Accountants
FRN:- 122480W**



**RADHESHAM AGRAWAL
PARTNER
Membership No. 118336**



**Place:Pune
Date:30/05/2017.**

VARDHAMAN LABORATORIES LIMITED

REGD.OFFICE-1393,PETH BHAG,HIGH SCHOOL ROAD,SANGLI 416 416 E-MAIL-vll@vsnl.com
CIN :- L85195PN1985PLC036017

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH -2017

SCRIP CODE : 524796

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year ended
		31/03/2017 (Audited)	31/12/2016 (Unaudited)	31/03/2016 (Audited)	31/03/2017 (Audited)
1	Income from Operations	-	-	-	-
	Net Sales/Income from operations	-	-	-	-
	Other Operating Income	-	-	-	-
	Total income from operations (net)	-	-	-	-
2	Expenses				
a	Cost of Material Consumed	-	-	-	-
b	Purchase of stock in trade	-	-	-	-
c	Change in inventories off finished goods, work in progress and stock in trade	-	-	-	-
d	Employee Benefits Expenses	-	-	-	-
e	Depreciation and Amortization Expense	-	-	-	-
f	Other Expenses	7.4195	1.9435	7.8958	7.4195
	Total Expenses	7.4195	1.9435	7.8958	7.4195
3	Profit/(Loss) from operations before other income, finance cost & Exceptional Item (1-2)	(7.4195)	(1.9435)	(7.8958)	(7.4195)
4	Other Income	3.7018	0.9257	4.7543	3.7018
5	Profit/(Loss) from ordinary activities before finance cost & Exceptional Items (3+/-4)	(3.7177)	(1.0178)	(3.1415)	(3.7177)
6	Finance Cost	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance cost but before Exceptional Item (5+/-6)	(3.7177)	(1.0178)	(3.1415)	(3.7177)
8	Exceptional Items	-	-	-	-
9	Profit/(Loss) from ordinary activities before Tax (7+/-8)	(3.7177)	(1.0178)	(3.1415)	(3.7177)
10	Tax Expenses	-	-	-	-
11	Net Profit/(Loss) from ordinary activities after Tax (9+/-10)	(3.7177)	(1.0178)	(3.1415)	(3.7177)
12	Extraordinary Item (Net of Tax)	-	-	-	-
13	Net Profit/(Loss) for the period (11+/-12)	(3.7177)	(1.0178)	(3.1415)	(3.7177)
14	Share of Profit / (loss) of associates	-	-	-	-
15	Minority interest	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+/-14+/-+16)	(3.7177)	(1.0178)	(3.1415)	(3.7177)
17	Paid up Capital (Rs.10/- each fully paid)	412.47	412.47	412.47	412.47
18	Reserve Excluding Revaluation Reserve as per balancesheet of previous accounting year	-	-	-	-
19 (i)	Earning per Share (Before Extraordinary items) (of Rs. 10/- each)(not annualised)				
a	Basic	(0.09)	(0.02)	(0.08)	(0.09)
b	Diluted	(0.09)	(0.02)	(0.08)	(0.09)
19(ii)	Earning per Share (After Extraordinary items) (of Rs. 10/- each)(not annualised)				
a	Basic	(0.09)	(0.02)	(0.08)	(0.09)
b	Diluted	(0.09)	(0.02)	(0.08)	(0.09)

Notes :

<input type="checkbox"/>	The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on May 30, 2017 and were approved and taken on record at the meeting of the Board of Directors of the Company held on that date.
<input type="checkbox"/>	The Statutory Auditor has carried out Audit of the above results.
<input type="checkbox"/>	The Company has only one segment which is Pharmaceuticals. Therefore disclosure relating to segment is not applicable and accordingly not made.
<input type="checkbox"/>	Figures for previous quarters/period have been regrouped /restated where necessary.

Place : SANGLI
Date : 30/05/2017

For VARDHAMAN LABORATORIES LTD.


SUNIL SHAH
Managing Director

VARDHAMAN LABORATORIES LIMITED

REGD.OFFICE-1393,PETH BHAG,HIGH SCHOOL ROAD,SANGLI 416 416 E-MAIL-vll@vsnl.com
CIN :- L85195PN1985PLC036017

STATEMENT OF ASSETS AND LIABILITIES FOR THE QUARTER AND YEAR ENDED MARCH -2017

	PARTICULARS	As at Year End 31/03/2017 Audited	As at Year End 31/03/2016 Audited
A	Equity And Liabilities		
1	Shareholders' Funds		
	(a) Share Capital	412.47	412.47
	(b) Reserve and Surplus	(208.62)	(204.90)
	Sub-Total - Shareholders' Fund	203.85	207.56
2	Share Application Money pending Allotment	-	-
3	Minority Interest*	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	-	-
	(b) Deffered Tax Liability	-	-
	(c) Other long term liability	-	-
	(d) Long Term Provisions	-	-
	Sub-Total - Non-Current Liabilities	-	-
5	Current Liabilities		
	(a) Short Term Borrowings	-	-
	(b) Trade Payables	-	-
	(c) Other Current Liabilities	1.20	2.31
	(d) Short Term Provisions	-	-
	Sub-Total - -Current Liabilities	1.20	2.31
	Total Equity And Liabilities	205.05	209.88
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets	-	-
	(b) Godwill on consolidation	-	-
	(c) Non-Current Investments	-	-
	(d) Deffered Tax Assets	-	-
	(e) Long Term Loans and Advances	-	-
	(f) Other non current assets	-	-
	Sub-Total - Non-Current Assets	-	-
2	Current Assets		
	(a) Current Investment	-	-
	(b) Inventories	-	-
	(c) Trade Receivables	155.55	155.30
	(d) Cash and Cash Equivalents	48.20	53.39
	(e) Short Term Loan and Advances	0.86	0.68
	(f) Other Current Assets	0.44	0.52
	Sub-Total - Current Assets	205.05	209.88
	Total - Assets	205.05	209.88

Notes :

<input type="checkbox"/>	The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on May 30, 2017 and were approved and taken on record at the meeting of the Board of Directors of the Company held on that date.
<input type="checkbox"/>	The Statutory Auditor has carried out Audit of the above results.
<input type="checkbox"/>	The Company has only one segment which is Pharmaceuticals. Therefore disclosure relating to segment is not applicable and accordingly not made.
<input type="checkbox"/>	Figures for previous quarters/period have been regrouped /restated where necessary.

Place : SANGLI
Date : 30/05/2017

For VARDHAMAN LABORATORIES LTD.


SUNIL SHAH,
Managing Director

VARDHAMAN

Vardhaman Laboratories Limited

REGD. OFFICE : 1393, Peth-Bhag, High School Road, P.O.Box 184, SANGLI 416 416.
Tel: (0233) 2623886, 2623310 Fax: (0233) 2620467 E-mail : vll@vsnl.com
FACTORY : J-5, MIDC, Kupwad, SANGLI 416 436.

L85195PN1985PLC036017

26th July, 2017

To,

The Secretary
Bombay Stock Exchange Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001

Dear Sirs,

Ref.:- Scrip Code 524796

Sub.:- Disclosure of the Impact of Audit Qualifications by the Listed Entities under Regulation 33/52 of SEBI (LODR), (Amendment) Regulations, 2016.

Dear Sir,

Pursuant to SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 we hereby confirm that M/s. Agrawal Naredi & Co., Statutory Auditors of the Company, have provided unqualified audit opinion on the standalone financial results of the Company for the year ended March 31, 2017.

This is for your record.

Thanking You,

Yours Sincerely,
For Vardhaman Laboratories Limited


Sunil Shah
Managing Director
(DIN:00321471)